GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » eFFECTOR Therapeutics Inc (FRA:LWK) » Definitions » EV-to-FCF

eFFECTOR Therapeutics (FRA:LWK) EV-to-FCF : -0.11 (As of May. 23, 2024)


View and export this data going back to 2021. Start your Free Trial

What is eFFECTOR Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, eFFECTOR Therapeutics's Enterprise Value is €2.90 Mil. eFFECTOR Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €-27.07 Mil. Therefore, eFFECTOR Therapeutics's EV-to-FCF for today is -0.11.

The historical rank and industry rank for eFFECTOR Therapeutics's EV-to-FCF or its related term are showing as below:

FRA:LWK' s EV-to-FCF Range Over the Past 10 Years
Min: -58.73   Med: 0.81   Max: 1.23
Current: -0.11

During the past 4 years, the highest EV-to-FCF of eFFECTOR Therapeutics was 1.23. The lowest was -58.73. And the median was 0.81.

FRA:LWK's EV-to-FCF is ranked worse than
100% of 370 companies
in the Biotechnology industry
Industry Median: 9.66 vs FRA:LWK: -0.11

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-23), eFFECTOR Therapeutics's stock price is €1.64. eFFECTOR Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-12.091. Therefore, eFFECTOR Therapeutics's PE Ratio for today is At Loss.


eFFECTOR Therapeutics EV-to-FCF Historical Data

The historical data trend for eFFECTOR Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

eFFECTOR Therapeutics EV-to-FCF Chart

eFFECTOR Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- -12.22 -0.45 -1.25

eFFECTOR Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.60 -1.48 -1.30 -1.25 -1.74

Competitive Comparison of eFFECTOR Therapeutics's EV-to-FCF

For the Biotechnology subindustry, eFFECTOR Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


eFFECTOR Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, eFFECTOR Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where eFFECTOR Therapeutics's EV-to-FCF falls into.



eFFECTOR Therapeutics EV-to-FCF Calculation

eFFECTOR Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=2.897/-27.074
=-0.11

eFFECTOR Therapeutics's current Enterprise Value is €2.90 Mil.
eFFECTOR Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-27.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


eFFECTOR Therapeutics  (FRA:LWK) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

eFFECTOR Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.64/-12.091
=At Loss

eFFECTOR Therapeutics's share price for today is €1.64.
eFFECTOR Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-12.091.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


eFFECTOR Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of eFFECTOR Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


eFFECTOR Therapeutics (FRA:LWK) Business Description

Traded in Other Exchanges
Address
142 North Cedros Avenue, Suite B, Solana Beach, CA, USA, 92075
eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs).

eFFECTOR Therapeutics (FRA:LWK) Headlines

No Headlines